The use of acetarsone as an antisyphilitic drug which could be taken by mouth has been reviewed recently by Pillsbury and Perlman,1 who studied 187 cases of congenital syphilis at the Sigma Clinic of the Children's Hospital, University of Pennsylvania School of Medicine. Their conclusions corroborate the previous statements made by the Council on Pharmacy and Chemistry2 concerning the use of acetarsone in the treatment of syphilis. The investigators emphasize that acetarsone, although an active antisyphilitic agent by mouth, is less rapid in action than arsphenamine and is inferior to both arsphenamine and bismuth preparations in arresting congenital syphilis. In their series of cases they found a high incidence of reactions. They concluded, indeed, that adequate experimental background for determination of the toxicity and spirocheticidal effect of individual lots of acetarsone is not available. In addition they observed that regularity of attendance of patients at the clinic was
WHY ACETARSONE FOR SYPHILIS? JAMA. 1939;113(22):1969–1970. doi:10.1001/jama.1939.02800470045013
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: